PRCT Stock Plunges 15% as PROCEPT Slashes Guidance Amid Commercial Turmoil
PROCEPT BioRobotics faces securities fraud investigation after missing Q4 2025 revenue and slashing 2026 guidance by $20-40 million, prompting 15% stock decline.
PRCTsecurities fraudclass action lawsuit

